Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Pee predicts cancer treatment success?

NCT ID NCT06904677

Knowledge-focused Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at whether proteins in urine can help doctors predict how patients with advanced colorectal cancer will respond to treatment given before surgery. Researchers will collect urine samples from 400 participants before and after therapy and use advanced technology to find protein markers linked to tumor shrinkage. The goal is to develop a non-invasive way to guide treatment decisions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 400 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

May 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

This study will enroll patients aged 18 to 75 years with a pathologically confirmed diagnosis of locally advanced colorectal cancer (LACC), defined as clinical stage cT3-4 and/or N+ without distant metastasis (M0) as determined by imaging (CT and/or PET-CT). Eligible participants must be treatment-naïve, with no prior exposure to anti-tumor therapies such as chemotherapy, targeted therapy, or immunotherapy. All patients must be clinically assessed as suitable candidates for neoadjuvant therapy followed by surgical resection and must be able to tolerate and complete the prescribed treatment regimen. In addition, participants must be willing and able to provide urine samples before and after neoadjuvant therapy and must sign written informed consent prior to enrollment. Patients will be excluded if they have a history of or concurrent diagnosis of other malignancies; suffer from serious hepatic, renal, cardiovascular, or metabolic conditions that may interfere with urinary protein metab

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged 18-75 years; 2. Pathologically confirmed diagnosis of locally advanced colorectal cancer (cT3-4 and/or N+); 3. Planned to undergo neoadjuvant therapy followed by surgical resection; 4. No evidence of distant metastasis (M0) confirmed by imaging (CT and/or PET-CT); 5. Clinically assessed as being able to tolerate and complete the full course of neoadjuvant treatment; 6. No prior anti-tumor therapy (e.g., targeted therapy, immunotherapy) before the initiation of treatment; 7. Willing and able to provide urine samples as required; 8. Written informed consent obtained. Exclusion Criteria: 1. History of or concurrent diagnosis with other malignancies; 2. Presence of severe hepatic, renal, cardiovascular, or metabolic diseases that may affect urinary protein metabolism; 3. Recent use of medications known to affect protein metabolism (e.g., glucocorticoids, high-dose antibiotics); 4. Urinary tract infection or other diseases known to cause abnormal urinary protein levels (e.g., nephrotic syndrome); 5. Any other condition deemed unsuitable for enrollment by the investigators.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Colorectal cancer (CRC) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Colorectal cancer (CRC) Neoadjuvant therapy Proteomics

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cancer Hospital Chinese Academy of Medical Sciences

    RECRUITING

    Beijing, Chaoyang District, 100021, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.